News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Biocon has reported consolidated financial results for the period ended December 31, 2021
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Narayanan to lead SeQuent through next phase of consolidation and growth
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
